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• Pancreatic Ductal Adenocarcinoma (PDAC) causes 90% of pancreatic 
malignancies, with a 92% mortality rate
• Gemcitabine (GEM) is the primary cytotoxic chemotherapy treatment for PDAC. 
However, the apoptotic efficacy of GEM is reduced because GEM increases the 
phosphorylation of p65 and ERK
• Thrombomodulin (TM) has anti-inflammatory and cytoprotective effects via G-
protein coupled receptor 15 (GPR15)
• Recombinant Thrombomodulin (rTM), comprised of extracellular regions of TM, is 
approved to treat disseminated intravascular coagulation (DIC) in Japan
Step 1
• Quantify the GPR15 Expression in Pancreatic Cancer Cell Lines
• Western Blot Analysis
Step 2
• Measure the Efficacy of rTM and GEM Treatment based on GPR15 
expression
• MTT and Cell Proliferation Experiments
Step 3
• Determine the Mechanism Through Which rTM Inhibits Cell 
Proliferation and Enhances GEM-induced apoptosis
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Results
Results
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GPR15
β-Actin
We performed a western blot analysis to determine the GPR15 expression in HPNE 




































We assessed the effect 
of rTM treatment on cell 
proliferation by evaluating 
cell viability of HPNE and 
PDAC cell lines via MTT 
assay. The test illustrated that 
rTM significantly inhibited 
cells with high GPR15 


































We treated control PATC66 
cells and GPR15-
knockdown PATC66 cells 
with rTM. In the GPR15 
knockdown cells, rTM was 




































We analyzed the effect of 
GPR15 on rTM’s
enhancement of GEM with 
GPR15 knockdown PATC66 
cells. The MTT assay
illuminated that rTM enhanced 
GEM-induced cell inhibition 














We evaluated the effect 
of the rTM and GEM 
combination treatment on 
NF-kB and ERK activity 
in PATC66 cells with 
GPR15 knockdown. 
Western blot analysis 
maintained that rTM
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We used a western blot test 
to determine that rTM
enhanced the apoptotic 
effect of GEM in PATC66 
cells via PARP and 
caspase-9 cleavage 
rTM enhances the 
inhibition effect of 
GEM on cell 
proliferation




rTM inhibits cell 
proliferation by 
decreasing natural and 
GEM-induced p65 and 
ERK phosphorylation




PDAC Cell Line GPR15 Expressions







Due to high GPR15 
expression, PATC66 was used 
for all following tests
Statistical analysis
consisted of non-paired 
t-tests, and ANOVAs
GPR15 Mediation of  
rTM-Induced 
Inhibition of Cell 
Proliferation
We evaluated the 
effect of rTM and 
GEM combined on 
PATC66 cells with 
GPR15 expression 





inhibition effect of 
GEMDays
Control vs. rTM: P<0.0001





















rTM and GEM Treatment on Cell Proliferation
rTM and GEM Treatment on PDAC 










• In the presence of GPR15, rTM decreased the activation of conventional and 
GEM-induced NF-KB and ERK phosphorylation.
• rTM’s enhancement of GEM cytotoxicity and anti-tumor effect was dependent on 
GPR15, suggesting that GPR15 is a cell surface receptor
• rTM suppressed PDAC cell growth by inhibiting thrombin-induced PAR1 and NF-
KB activation 
• Since rTM is widely used in patients with DIC-induced poor bodily function to 
minimal side effects, achieving approval of rTM as a chemotherapy drug is less 
difficult
Conclusion
rTM had a significant anti-
tumor effect and enhanced 
GEM’s cytotoxicity of 
pancreatic cancer cells by 
inhibiting NF-KB and ERK 
activation via GPR15
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